Table 2.

Baseline characteristics of our study cohort

	N (%)	Median (IQR)	Reference values
Gender [Male %]	148	105 (70.9%)
Median age at initial diagnose [in years]	148	33.5 (26–47)
Median time of follow-up [in years]	148	9 (3–14)
Patients diagnosed with AIH/PSC overlap	5 (3.4%)
Presence of dominate stenosis	87 (58.8%)
Presence of IBD	99 (66.9%)
Histopathological proof	65 (43.9%).
Presence of type I diabetes	4 (2.7%)
OLT	32 (21.6%)
Re-OLT	9 (6.1%)
Death	37 (25%)
Combined end-point (OLT and death)	57 (38.5%)
CCA	12 (8.1%)
Bilirubin [mg/dl]	142	0.8 (0.56–1.6)	─ 1 mg/dl
ALT [IU/l]	145	98.1 (53.5–230.2)	─ 35 IU/l
AST [IU/l]	145	63.5 (32.5–120.5)	─ 37 IU/l
AP [IU/l]	142	265 (151.5–518.0)	40 ─ 130 IU/l
GGT [IU/l]	148	324.0 (151.5–681.5)	6 ─ 26 IU/l
Albumin [g/dl]	137	44.0 (40.0. – 46.0)	30 ─ 50 g/dl
Serum-IgG levels [g/l]	148	14.9 (12.0–20.2)	─ 16 g/l
Mayo risk score	148	−0.2 (−3.1–2.3)
MELD	142	6 (6–15)

Abbreviation: AIH/PSC = autoimmune hepatitis/primary sclerosing cholangitis, IBD = inflammatory bowel disease, OLT = orthotopic liver transplantation, CCA = cholangiocarcinoma, ALT = alanine aminotransferase, AST = aspartate aminotransferase, AP = alkaline phosphatase, GGT = y-glutamyl-transferase, MELD score = Model for End-stage Liver Disease